Grace Therapeutics, Inc. Deferred Tax Relating To Items Charged Or Credited Directly To Equity
Grace Therapeutics, Inc. (GRCE) had Deferred Tax Relating To Items Charged Or Credited Directly To Equity of CAD 129.00 thousand as of 2017-02-21, per its 20-F filed 2019-06-26.
Discontinued › Notes › Income Taxes
ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2019-06-26
- 2017-02-21: Deferred Tax Relating To Items Charged Or Credited Directly To Equity 129.00K CAD.
| Period end | Deferred Tax Relating To Items Charged Or Credited Directly To Equity |
|---|---|
| 2017-02-21 | 129.00K CAD 20-F · filed 2019-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |